Cocrystal Pharma, Inc.
COCPHealthcare|Biotechnology|US
$1.04
+0.04 (+4.00%)
DCF Value
$0.47
Tangible Book / Share
$0.08
Cash / Share
$0.16
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03501550 Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) | Chronic Hepatitis C | P2 | Completed | 12 | Open-label | CDI-31244, SOF/VEL |
| NCT06160531 Influenza Viral Challenge Study of CC-42344 in Healthy Participants | Influenza A | P2 | Completed | 78 | RCT, Double-blind | CC-42344, Placebo |
| NCT07198139 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus | Norovirus | P1P2 | Completed | 32 | RCT, Double-blind | CDI-988, Placebo |
| NCT05202379 CC-42344 Safety Study in Healthy Participants | Influenza A | P1 | Completed | 80 | RCT, Double-blind | CC-42344, Placebo |
| NCT05977140 CDI-988 Safety Study in Healthy Participants | Healthy Volunteers | P1 | Completed | 94 | RCT, Double-blind | CDI-988, Placebo |
| NCT02760758 A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects | Hepatitis C | P1 | Completed | 76 | RCT, Double-blind | CDI-31244, Placebo |